CoChat

Towards Treatment of Stargardt Disease: Workshop Organized and Sponsored by the Foundation Fighting Blindness

Open access
Sears, Avery E., Bernstein, Paul S., Cideciyan, Artur V., Hoyng, Carel, Issa, Peter Charbel, Palczewski, Krzysztof, Rosenfeld, Philip J., Sadda, SriniVas, Schraermeyer, Ulrich, Sparrow, Janet R., Washington, Ilyas, Scholl, Hendrik P.N. · 2017 · Translational Vision Science & Technology
Cited by 68

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Accumulation of fluorescent metabolic byproducts of the visual (retinoid) cycle is associated with photoreceptor and retinal pigment epithelial cell death in both Stargardt disease and atrophic (nonneovascular) age-related macular degeneration (AMD). As a consequence of this observation, small molecular inhibitors of enzymes in the visual cycle were recently tested in clinical trials as a strategy to protect the retina and retinal pigment epithelium in patients with atrophic AMD. To address the clinical translational needs for therapies aimed at both diseases, a workshop organized by the Foundation Fighting Blindness was hosted by the Department of Pharmacology at Case Western Reserve University on February 17, 2017, at the Tinkham Veale University Center, Cleveland, OH, USA. Invited speakers highlighted recent advances in the understanding of the pathophysiology of Stargardt disease, in terms of its clinical characterization and the development of endpoints for clinical trials, and discussed the comparability of therapeutic strategies between atrophic age-related macular degeneration (AMD) and Stargardt disease. Investigators speculated that reducing the concentrations of visual cycle precursor substances and/or their byproducts may provide valid therapeutic options for the treatment of Stargardt disease. Here we review the workshop's presentations in the context of published literature to help shape the aims of ongoing research endeavors and aid the development of therapies for Stargardt disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1167/tvst.6.5.6

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 68

Metadata

Authors
Sears, A. E., Bernstein, P. S., Cideciyan, A. V., Hoyng, C., Issa, P. C., Palczewski, K., Rosenfeld, P. J., Sadda, S., Schraermeyer, U., Sparrow, J. R., Washington, I., & Scholl, H. P. N.
Venue
Translational Vision Science & Technology
Published
2017-09-14
Volume
6
Issue
5
Pages
6
ISSN
2164-2591 (ISSN-L)
OpenAlex
W2755243141
Cited by
68
References
16
FWCI
2.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Towards Treatment of Stargardt Disease: Workshop Organized and Sponsored by the Foundation Fighting Blindness. https://app.cochat.ai/papers/10.1167/tvst.6.5.6
The paper
Sears, A. E., Bernstein, P. S., Cideciyan, A. V., Hoyng, C., Issa, P. C., Palczewski, K., Rosenfeld, P. J., Sadda, S., Schraermeyer, U., Sparrow, J. R., Washington, I., & Scholl, H. P. N. (2017). Towards Treatment of Stargardt Disease: Workshop Organized and Sponsored by the Foundation Fighting Blindness. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.6.5.6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.